S21-084 Methods to improve CAR T cell efficacy and safety by modulating mediators of phagocytosis There are several barriers to widespread use of CAR T-cell therapy. One of them is toxicity, primarily cytokine release syndrome (CRS) and neurologic toxicity, but also on-target off-tumor toxicity. Johanna Theruvath Crystal Mackall Elena Sotillo